Biocon gets six-month extension on insulin supply pact in Malaysia
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Standalone profit from operations for the quarter were Rs. 162 crores
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard
Rising demands and advancements in eye care drive growth
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Subscribe To Our Newsletter & Stay Updated